BASF Increases Prices for Nature-Identical Carotenoids for Human and Animal Nutrition, Excluding Astaxanthin
Advertisement
BASF globally increases prices for all nature-identical carotinoid formulations containing canthaxanthin, citranaxanthin, C30-ester and beta-carotene by approximately 12%, effective immediately or as existing commitments allow.
The products affected are all grades for human and animal nutrition including Lucarotin®, Beta-Carotene, Lucantin® Red, Lucantin® Yellow and Lucantin® CX Forte. All existing contractual obligations will be honored. Lucantin® Pink (astaxanthin) is not affected.
This increase is necessary to compensate for negative impacts resulting from a combination of increased energy and raw material prices, higher logistics costs and negative exchange rate effects.
Most read news
Other news from the department price development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
BASF increases prices for pharmaceutical excipients and active ingredients
Evonik increases prices of pharmaceutical amino acids
Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
BASF increases prices for pharmaceutical excipients and active ingredients
Evonik increases prices of cGMP-grade amino acids
BASF increases prices for vitamin B2
Significant overall survival benefit observed with radium 223 in patients with castration-resistant prostate cancer
Revolutionary Pan-Genome Analysis of Lactic Acid Bacteria Unveils Promising Opportunities for Food Industry and Healthcare
Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million
Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
Lonza expands bioconjugation in Visp with two additional manufacturing suites